title: Intervention of rosiglitazone on myocardium Glut-4 mRNA expression during ischemia-reperfusion injury in cardio-pulmonary bypass in dogs.
abstract: During cardiac pulmonary bypass (CPB), myocardial ischemia-reperfusion (I/R) induces heart glucose metabolism impairment. Our previous research showed that the decreased glucose utilization is due to decreased glucose transporter-4 (Glut-4) expression and translocation to myocyte surface membranes. This study further examined whether rosiglitazone, a synthetic agonist of peroxisome proliferator-activated receptor γ, could intervene glucose metabolism by regulating Glut-4 mRNA during I/R in dogs. Cardiac ischemia was induced by cardiopulmonary bypass for 30 or 120 min. Plasma insulin and glucose concentrations were measured at pre-bypass (control), aortic cross-clamp off (I/R) at 15, 45, and 75 min. The left ventricle biopsies were taken for the expression of Glut-4 mRNA by real-time RT-PCR. In dogs receiving 120 min ischemia, coronary arterial, venous glucose concentrations, plasma insulin levels, and insulin resistant index (IRI) were increased, but the expression of Glut-4 mRNA was decreased obviously at 15 min of reperfusion, and recovered gradually. On the other hand, these changes were relatively mild in dogs treated with rosiglitazone in cardioplegic solution and expression of Glut-4 mRNA was increased remarkably. It is concluded that the decrease in total amount of Glut-4 mRNA expression could be one of the important molecular mechanisms, which causes the myocardium insulin resistance. The longer the ischemia period, the decrease in amount of Glut-4 mRNA was more dramatic. Adding rosiglitazone into the cardioplegic solution during I/R can increase the amount of Glut-4 mRNA expression, mitigate the myocardium insulin resistance and improve the myocardium I/R injury during CPB.
authors.affiliation: Thoracic and Cardiovascular Surgery, Affiliated Hospital of Zunyi Medical College, 149 Da-Lian Road, Zunyi 563003, Guizhou, People's Republic of China.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.forename: Guiyou
authors.initials: G
authors.lastname: Liang
authors.forename: Gang
authors.initials: G
authors.lastname: Xu
authors.forename: Daxin
authors.initials: D
authors.lastname: Liu
authors.forename: Qingyong
authors.initials: Q
authors.lastname: Cai
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Gao
mesh_terms: D000818:Animals; D001786:Blood Glucose; D002314:Cardioplegic Solutions; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D004285:Dogs; D015870:Gene Expression / Q000187:drug effects; D051275:Glucose Transporter Type 4 / Q000235:genetics* / Q000378:metabolism; D006352:Heart Ventricles / Q000378:metabolism* / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000378:metabolism*; D047495:PPAR gamma / Q000819:agonists; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D017725:Ventricular Pressure
chemical_list: D001786:Blood Glucose; D002314:Cardioplegic Solutions; D051275:Glucose Transporter Type 4; D007328:Insulin; D047495:PPAR gamma; D012333:RNA, Messenger; D045162:Thiazolidinediones; D000077154:Rosiglitazone